Principles of Adjuvant Chemotherapy for Bone and Soft Tissue Tumors

  • Shuichi Fujimoto
Conference paper


The recent progress in the success of therapeutic effects on osteogenic sarcoma has been extraordinary and greatly enhanced by the contribution of adjuvant chemotherapy [1]. The number of treatment courses in adjuvant chemotherapy that will be adequate to eradicate all tumor cells has become a matter of concern. The principles involved in this matter and a tentative conclusion are presented by an analysis of the therapeutic results of 48 patients with osteogenic sarcoma.


Adjuvant Chemotherapy Osteogenic Sarcoma Soft Tissue Tumor Tumor Cell Kill Microscopic Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221–1230Google Scholar
  2. 2.
    Skipper H, Schabel FM Jr, Wilcox WS (1964) Experimental evaluation of potential anticancer agents. XIV. Further study of certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother Rep 45: 5–28Google Scholar
  3. 3.
    Rosen G (1985) Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: A ten-year experience. Orthopedics 8: 659–664PubMedGoogle Scholar
  4. 4.
    Frei E, Jaffe N, Gero M, Skipper H, Watts H (1978) Adjuvant chemotherapy of osteogenic sarcoma: Progress and perspectives. J Natl Cancer Inst 60: 3–10Google Scholar
  5. 5.
    Cortes EP, Holland JF, Wang JJ, Glidewell 0 (1975) Adriamycin (NSC-123127) in 87 patients with osteosarcoma. Cancer Chemother Rep 6 (Part 3): 305–313Google Scholar
  6. 6.
    Ochs JJ, Freeman AI, Douglass HO Jr, Higby DS, Mindell ER, Sinks LF (1978) Cis-dichlorodiammine-platinum ( II) in advanced osteogenic sarcoma. Cancer Treat Rep 62: 239–245Google Scholar
  7. 7.
    Vogl S, Ohnuma T, Perloff M, Holland J (1976) Combination chemotherapy with Adriamycin and cis-diamminedichloroplatinum in patients with neoplastic disease. Cancer 38: 21–26PubMedCrossRefGoogle Scholar
  8. 8.
    Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos A (1976) Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 43: 2163–2177Google Scholar
  9. 9.
    Colvin M, Brundrett RB, Kan MNN, Jardine I, Fenselau C (1976) Alkylating properties of phosphoramide mustard. Cancer Res 36: 1121–1126PubMedGoogle Scholar
  10. 10.
    Shimoyama M, Niitani H, Kimura K (1975) Chemotherapeutic effect of cyclophosphamide and its related active compounds. 3. A design of optimal therapeutic schedules of these compounds (in Japanese). Jpn J Cancer Chemother 2: 889–901Google Scholar
  11. 11.
    Bagley CM Jr, Bostick FW, DeVita VT Jr (1973) Clinical pharmacology of cyclophosphamide. Cancer Res 33: 226–233PubMedGoogle Scholar
  12. 12.
    Frei E III, Freireich EJ (1965) Progress and perspectives in the chemotherapy of acute leukemia. Adv Chemother 2: 269–298PubMedGoogle Scholar
  13. 13.
    Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733PubMedGoogle Scholar
  14. 14.
    Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66: 439–449PubMedGoogle Scholar

Copyright information

© Springer Japan 1992

Authors and Affiliations

  • Shuichi Fujimoto
    • 1
  1. 1.Division of ChemotherapyChiba Cancer Center Research InstituteChibaJapan

Personalised recommendations